Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation: A multicenter study of its status and influential factors

Circulation Journal

Volumn 75, Issue 9, 2011, Pages 2087-2094

  Okumura, Ken ^a   Komatsu, Takashi ^b   Yamashita, Takeshi ^c   Okuyama, Yuji ^d   Harada, Masahiko ^e   Konta, Yoshiyuki ^f   Hatayama, Toru ^g   Horiuchi, Daisuke ^a   Tsushima, Eiki ^h  

^a HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^b IWATE MEDICAL UNIVERSITY   (Japan)

^c THE CARDIOVASCULAR INSTITUTE   (Japan)

^d OSAKA GENERAL MEDICAL CENTER   (Japan)

^e UBE INDUSTRIES LTD   (Japan)

^f Reimeikyo Rehabilitation Hospital   (Japan)

^g Hatayama Clinic   (Japan)

^h HIROSAKI UNIVERSITY   (Japan)

Author keywords

Anticoagulants; Atrial fibrillation; Stroke

Indexed keywords

ANTITHROMBOCYTIC AGENT; WARFARIN;

ADULT; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG EFFECT; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; JAPANESE; MAJOR CLINICAL STUDY; MALE; PROTHROMBIN TIME; RISK FACTOR; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; JAPAN; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; WARFARIN;

EID: 80052156633     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0350     Document Type: Article

References (23)

1. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A metaanalysis. Ann Intern Med 1999; 131: 492-501.
2. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Circulation 2006; 114: e257-e354.
3. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12: 1360-1420.
4. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): Digest version. Circ J 2010; 74: 2479-2500.
5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
6. Hori M, Connolly SJ, Ezekowitz, MD, Reilly PA, Yusuf S, Wallentin L, et al. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation: Sub-analysis in Japanese population in RE-LY trial. Circ J 2011; 75: 800-805.
7. Wann LS, Curtis AB, Ellenbogen KA, Estes NAM 3rd, Ezekowitz MD, Jackman WM, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123: 1144-1150.
8. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026.
9. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: A systematic review and metaregression. Chest 2006; 129: 1155-1166.
10. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239.
11. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: Results from SPORTIF III and V. Arch Intern Med 2007; 167: 239-245.
12. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-2037.
13. Froom P, Miron E, Barak M. Oral anticoagulants in the elderly. Br J Haematol 2003; 120: 526-528.
14. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med 1994; 121: 676-683.
15. Wittkowsky AK. Effective anticoagulation therapy: Defining the gap between clinical studies and clinical practice. Am J Manag Care 2004; 10: S297-S306.
16. Friberg L, Hammar N, Ringh M, Pettersson H, Rosenqvist M. Stroke prophylaxis in atrial fibrillation: Who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). Eur Heart J 2006; 27: 1954-1964.
17. Gattellari M, Worthington J, Zwar N, Middleton S. Barriers to the use of anticoagulation for nonvalvular atrial fibrillation: A representative survey of Australian family physicians. Stroke 2008; 39: 227-230.
18. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
19. Inoue H. Antithrombotic therapy: ESC guidelines vs JCS guidelines. Circ J 2010; 74: 2542-2545.
20. Masaki N, Suzuki M, Matsumura A, Maruyama Y, Hashimoto Y. Quality of warfarin control affects the incidence of stroke in elderly patients with atrial fibrillation. Intern Med 2010; 49: 1711-1716.
21. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial. Lancet 2010; 376: 975-983.
22. Toyoda K, Yasaka M, Iwade K, Nagata K, Koretsune Y, Sakamoto T, et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: A prospective, multicenter, observational study. Stroke 2008; 39: 1740-1745.
23. Atarashi H, Inoue H, Okumura K, Yamashita T, Origasa H, and for the J-RHYTHM Registry Investigators. Investigation of optimal anticoagulation strategy for stroke prevention in Japanese patients with atrial fibrillation: The J-RHYTHM Registry study design. J Cardiol 2011; 57: 95-99.